The long non‐coding RNA KDM4A ‐ AS1 protects β‐cell function via the miR ‐423‐5p/growth differentiation factor 11 axis
Authors' conclusion
This study reveals that KDM4A-AS1 protects β-cell function through the miR-423-5p/GDF11 axis, providing a new potential target for the diagnosis and treatment of T2DM.
Study context
- Population
- Patients with T2D and healthy controls; pancreatic β cells in vitro
- Participants
- 98 vs 91
- Comparison
- T2D patients vs healthy controls; KDM4A-AS1 overexpression in β cells
- T2DMn = 98
- Healthy controlsn = 91reference
Methodological detailscase-control serum study, in vitro experiments
- Case-control serum study
- In vitro experiments
Main finding
As reported in the abstract
- In T2D serum, KDM4A-AS1 and GDF11 expression significantly downregulated and miR-423-5p significantly upregulated
- KDM4A-AS1 level negatively correlated with fasting plasma glucose (FPG) and HbA1c
- KDM4A-AS1 has good diagnostic value for T2D
- In vitro, KDM4A-AS1 overexpression promoted Ins1 and Ins2 expression, increased glucose-stimulated insulin secretion and cell proliferation, and reduced apoptosis
- KDM4A-AS1 directly targets miR-423-5p and protects β cells by regulating downstream GDF11
Original publication
The long non‐coding RNA KDM4A ‐ AS1 protects β‐cell function via the miR ‐423‐5p/growth differentiation factor 11 axis. Diabet Med. Published 3 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →